Growing cancer prevalence coupled with rising acceptance of targeted therapy to fuel market growth at a CAGR of ~12% from 2020 to 2028. The market growth is driven by growing adoption of targeted therapy over traditional therapy coupled with rising mAbs demand.
Adroit Market Research report on global immuno oncology assays market gives a holistic view of the market from 2018 to 2028, which includes factors such as market drivers, restraints, opportunities, and challenges. The market has been studied for historic years from 2018, with the base year of estimation as 2019 and forecast from 2020 to 2028. The report covers the current status and future traits of the market at global as well as country level. In addition, the study also assesses the market competition with Porter's five forces analysis and company positioning based on their product portfolio, geographic footprint, strategic initiatives and overall revenue. Prominent players operating in the global immuno oncology assays market have been studied in detail.
A widespread variety of analytical methods across diverse matrices, including blood cells, tumor, and DNA/RNA, are needed to describe the best, most revealing picture when it comes to immuno-oncology assessments. Options involve testing circulating proteins in the blood using immunoassays; evaluating the blood 's cellular portion, including analyzing circulating tumor cells and/or circulating free DNA by flow cytometry; and PCR expression of tumor genes
North America currently holds the largest share in Immuno Oncology Assays market owing to the presence of significant number of major players across the region along with growing investments by the established firms. Furthermore, Asia Pacific is going to record growth at a faster pace on account of rising awareness levels of cancer, and growing interest of major giants to explore opportunities across emerging economies of India, and China in particular.
The scope of the report is segmented into product, technology, indication, applications, and region. Some of the notable players operating across the global immuno oncology assays market includes F. Hoffmann-La Roche Ltd., Abbott, Merck KGaA, Agilent Technologies, Thermo Fisher Scientific, Inc., QIAGEN, bioMérieux SA, Illumina, Inc., PerkinElmer Inc., Randox Laboratories Ltd. among other prominent players.
Key segments of the global immuno oncology assays market
Product Overview, 2018-2028 (USD Billion)
Technology Overview, 2018-2028 (USD Billion)
- Flow Cytometry
- Next Generation Sequencing
Indication Overview, 2018-2028 (USD Billion)
- Lung Cancer
- Colorectal Cancer
- Other Cancers
Applications Overview, 2018-2028 (USD Billion)
- Clinical Diagnostics
Regional Overview, 2018-2028 (USD Billion)
- North America
- United Kingdom
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- Rest of Middle East and Africa